{"id":156369,"date":"2021-12-21T01:45:46","date_gmt":"2021-12-21T06:45:46","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/first-patient-dosed-in-study-of-targeted-alpha-therapy-candidate-for-bladder-cancer\/"},"modified":"2024-08-18T11:43:47","modified_gmt":"2024-08-18T15:43:47","slug":"first-patient-dosed-in-study-of-targeted-alpha-therapy-candidate-for-bladder-cancer","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/first-patient-dosed-in-study-of-targeted-alpha-therapy-candidate-for-bladder-cancer.php","title":{"rendered":"First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer"},"content":{"rendered":"<p><![CDATA[MELBOURNE, Australia and NANTES, France, Dec.  20, 2021  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (\u2018ATONCO\u2019) today announce that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Canc\u00e9rologie de l\u2019Ouest (ICO) in St Herblain, France.]]><\/p>\n<p>See the article here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/12\/20\/2355681\/0\/en\/First-Patient-Dosed-in-Study-of-Targeted-Alpha-Therapy-Candidate-for-Bladder-Cancer.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer\">First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the article here: First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/first-patient-dosed-in-study-of-targeted-alpha-therapy-candidate-for-bladder-cancer.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-156369","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156369"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=156369"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/156369\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=156369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=156369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=156369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}